Brief: Landos Biopharma Announces Positive Outcome Of End-Of-Phase 2 Meeting With The FDA

Landos Biopharma

14/06/2021 14:40

June 14 (Reuters) - Landos Biopharma Inc  LABP.O :
    * LANDOS BIOPHARMA ANNOUNCES POSITIVE OUTCOME OF
END-OF-PHASE 2
MEETING WITH THE FDA FOR OMILANCOR IN MILD-TO-MODERATE ACTIVE
ULCERATIVE COLITIS (UC) PATIENTS
    * LANDOS - CO, FDA AGREED ON KEY ELEMENTS FOR REGULATORY
APPROVAL
FOR PIVOTAL PHASE 3 PROGRAM WITH OMILANCOR IN PATIENTS WITH
MILD-TO-MODERATE ACTIVE UC

Source text for Eikon:  ID:nGNX6lZbSG 
Further company coverage:  LABP.O 

 ((Reuters.Briefs@thomsonreuters.com;))